ReciBioPharm, the Advanced Biologics division of Recipharm, has launched its new Process Analytical Technology (PAT) platform at this year’s Bio Summit. Recipharm is a Sweden-based pharmaceutical contract development and manufacturing organisation (CDMO).
The system is designed to support real-time process analytics and intelligent biomanufacturing, aiding quality control for the life sciences sector. Developed as part of Recipharm’s continuous manufacturing line for xRNA therapeutics, the innovative PAT platform is conceived to be mobile, modular, and smart.
This software transforms in-process raw data into actionable, real-time insights, enabling operators to optimise quality parameters immediately The new platform centralises quality analytics on a mobile skid and integrates multiple advanced analytical technologies alongside proprietary orchestration and management software.
This software transforms in-process raw data into actionable, real-time insights, enabling operators to optimise quality parameters immediately and streamline the route from development to patient delivery.
Vikas Gupta, President of ReciBioPharm, said: “We designed the PAT platform to fundamentally shift how manufacturers approach analytical testing. It’s about putting insights directly into the hands of those running the process, optimising quality in real time, and enabling scalable, sustainable biomanufacturing.”
The stackable, compact system is vendor-agnostic, modality-flexible, and future-proof, built to support existing and emerging analytical technologies. Its open-source modelling library supports diverse machine learning, mechanistic, and hybrid models. This prelaunch version can run multiple analyses concurrently and is configurable to support commercial-scale applications across therapeutic modalities.
Whether for process development or large-scale commercial manufacturing, ReciBioPharm’s PAT platform reduces overall process footprint, boosts efficiency, and cuts waste, paving the way for faster, more intelligent delivery of medicines.
It also features an open-source modelling library supporting machine learning, mechanistic, and hybrid models. In its current prelaunch configuration, the system can run multiple analyses simultaneously and is fully configurable to support commercial-scale manufacturing across a range of therapeutic modalities.
To learn about the newest innovations and industry updates for aseptic processing, attend talks from industry leaders and network with peers, reserve your seat for the Aseptic BioPharma Processing Summit in Vienna, Austria, on October 7-8, 2025.
For more information, visit our website or email us at info@innovatrix.eu for the event agenda. Visit our LinkedIn to stay up to date on our latest speaker announcements and event news.
Source:
